Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 1/2010

01-02-2010

The Role of Toll-Like Receptor Signaling in Human Immunodeficiencies

Authors: Hanna Suhir, Amos Etzioni

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2010

Login to get access

Abstract

Through the last decade, clinical immunology has witnessed a considerable progress in understanding the role of the innate immunity in human host defense, with Toll-like receptors (TLRs) being the most extensively innate immune receptors investigated. Growing literature documents the relevance of TLR signaling pathways to human disease, revealing a small, but expanding, group of new monogenic primary immunodeficiencies, in patients with various infectious diseases, previously considered as of unexplained “idiopathic” origin. Herein, we review these recently described deficiencies. Autosomal recessive IRAK-4 and myeloid differentiation factor 88 deficiencies were reported in 2003 and 2008, respectively, conferring predisposition to pyogenic bacterial infections, and autosomal recessive UNC93B1 and autosomal dominant TLR3 deficiencies were reported in 2006 and 2007, respectively, conferring predisposition to herpes simplex encephalitis. Furthermore, we highlight the published data associating TLR polymorphism with an altered susceptibility to infectious diseases.
Literature
1.
2.
Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5(10):987–995CrossRefPubMed
3.
Lemaitre B, Nicolas E, Michaut L et al (1996) The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86(6):973–983CrossRefPubMed
4.
5.
Kawai T, Akira S (2005) Pathogen recognition with Toll-like receptors. Curr Opin Immunol 17(4):338–344CrossRefPubMed
6.
O’Neill LA, Bowie AG (2007) The family of five: TIR-domain-containing adaptors in Toll-like receptor signaling. Nat Rev Immunol 7(5):353–364CrossRefPubMed
7.
Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124(4):783–801CrossRefPubMed
8.
Turvey SE, Hawn TR (2006) Towards subtlety: understanding the role of Toll-like receptor signaling in susceptibility to human infections. Clin Immunol 120(1):1–9CrossRefPubMed
9.
10.
11.
Beutler B (2004) Inferences, questions and possibilities in Toll-like receptor signaling. Nature 430(6996):257–63CrossRefPubMed
12.
Yamamoto M et al (2002) Essential role for TIRAP in activation of the signaling cascade shared by TLR2 and TLR4. Nature 420(6913):324–329CrossRefPubMed
13.
Horng T et al (2002) The adaptor molecule TIRAP provides signaling specificity for Toll-like receptors. Nature 420(6913):329–333CrossRefPubMed
14.
Yamamoto M et al (2003) Role of adaptor TRIF in the Myd88-independent Toll-like receptor signaling pathway. Science 301(5633):640–643CrossRefPubMed
15.
Yamamoto M et al (2003) TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol 4(11):1144–1150CrossRefPubMed
16.
Kawai T et al (2004) Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5(10):1061–1068CrossRefPubMed
17.
Doffinger R, Smahi A, Bessia C et al (2001) X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by NF-kappaB signaling. Nat Genet 27(3):277–285CrossRefPubMed
18.
Jain A, Ma CA, Liu S et al (2001) Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohidrotic ectodermal dysplasia. Nat Immunol 2(3):223–228CrossRefPubMed
19.
Zonana J, Elder ME, Schneider LC et al (2000) A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinenta pigmenti and due to mutations in IKK-gamma (NEMO). AM J hum Genet 67(6):1555–1562CrossRefPubMed
20.
Courtois G, Smahi A, Reichenbach J et al (2003) A hypomorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J Clin Invest 112(7):1108–1115PubMed
21.
Picard C, Puel A, Bonnet M et al (2003) Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299(5615):2076–2079CrossRefPubMed
22.
Casrouge A, Zhang SY, Eidenschenk C et al (2006) Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 314(5797):308–312CrossRefPubMed
23.
Zhang SY, Jouanguy E, Ugolini S et al (2007) TLR3 deficiency in patients with herpes simplex encephalitis. Science 317(5844):1522–1527CrossRefPubMed
24.
von Bernuth H, Picard C, Jin Z et al (2008) Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321(5889):691–696CrossRef
25.
Li S, Strelow A, Fontana EJ et al (2002) IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA 99(8):5567–5572CrossRefPubMed
26.
Suzuki N, Suzuki S, Duncan GS et al (2002) Severe impairment of interleukin-1 and Toll-like receptor signaling in mice lacking IRAK-4. Nature 416(6882):750–756CrossRefPubMed
27.
Kuglstatter A, Villasenor AG, Shaw D et al (2007) Cutting edge: IL-1 receptor-associated kinase 4 structures reveal novel features and multiple conformations. J Immunol 178(5):2641–2645PubMed
28.
Medvedev AE, Lentschat A, Kuhns DB et al (2003) Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 198(4):521–531CrossRefPubMed
29.
Picard C, von Bernuth H, Ku CL et al (2007) Inherited human IRAK-4 deficiency: an update. Immunol Res 38(1–3):347–352CrossRefPubMed
30.
Day N, Tangsinmankong N, Ochs H et al (2004) IRAK-4 deficiency associated with bacterial infections and failure to sustain antibody responses. J Pediatr 144(4):524–526CrossRefPubMed
31.
Ku CL, Picard C, Erdos M et al (2007) IRAK-4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J Med Genet 44(1):16–23CrossRefPubMed
32.
Ku CL, von Bernuth H, Picard C et al (2007) Human IRAK-4 deficiency: a selective predisposition to life-threatening pyogenic bacterial infections during childhood reveals an otherwise redundant role for TLRs in protective immunity. J Exp Med 204(10):2407–2422CrossRefPubMed
33.
Yang K, Puel A, Zhang S et al (2005) Human TLR-7, -8 and -9 mediated induction of IFN-alpha/beta and -lambda is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 23(5):465–478CrossRefPubMed
34.
Von Bernuth H, Ku CL, Rodriguez-Gallego C et al (2006) A fast procedure for the detection of defects in early Toll-like receptor signaling. Pediatrics 118(6):2498–2503CrossRef
35.
Gavin AL, Hoebe K, Betal D et al (2006) Adjuvant-enhanced antibody responses in the absence of TLR signaling. Science 314(5807):1936–1938CrossRefPubMed
36.
Pham LN, Dionne MS, Shirasu-Hiza M, Schneider DS (2007) A specific primed immune response in Drosophila is dependent on phagocytes. PLoS Pathog 3:e26CrossRefPubMed
37.
Zhang SY, Jouanguy E, Sancho-Shimizu V et al (2007) Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol Rev 220(1):225–236CrossRefPubMed
38.
Muller U, Steinhoff U, Reis LF et al (1994) Functional role of type 1 and type II interferons in antiviral defense. Science 264(5167):1918–1921CrossRefPubMed
39.
Jouanguy E, Zhang SY, Chapgier A et al (2007) Human primary immunodeficiencies of type I interferons. Biochimie 89(6–7):878–883CrossRefPubMed
40.
Vollstedt S, Arnold S, Schwerdel C et al (2004) Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes aimplex virus type 1. J Virol 78(8):3846–3850CrossRefPubMed
41.
42.
Nahmias AJ, Lee FK (2006) The natural history and epidemiology of herpes simplex viruses. In: Studahl M, Bergstrom T (eds) Herpes simplex viruses. Taylor & Francis, New York, pp 55–98
43.
Najioullah F, Bosshard S, Thouvenot D et al (2000) Diagnosis and surveillance of herpes simplex virus infection of the central nervous system. J Med Virol 61(4):468–473CrossRefPubMed
44.
45.
Sancho-Shimizu V, Zhang SY, Abel L et al (2007) Genetic susceptibility to herpes simplex virus 1 encephalitis in mice and humans. Curr Opin Clin Immunol 7(6):495–505CrossRef
46.
Tabeta K, Hoebe K, Jansen EM et al (2006) The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol 7(2):156–164CrossRefPubMed
47.
Brinkmann MM, Spooner E, Hoebe K et al (2007) The interaction between the ER membrane protein UNC93B and TLR3, 7 and 9 is crucial for TLR signaling. J Cell Biol 177(2):265–275CrossRefPubMed
48.
Kim YM, Brinkmann MM, Paquet ME et al (2008) UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 452(7184):234–240CrossRefPubMed
49.
Wintergerst U, Gangemi JD, Whitley S et al (1999) Effects of recombinant human IFN alpha in combination with acyclovir in experimental HSV-1 encephalitis. Antiviral Res 44(1):75–78CrossRefPubMed
50.
Casanova JL, Abel L (2002) Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 20:581–620CrossRefPubMed
51.
Casanova JL, Abel L (2004) The human model: a genetic dissection of immunity to infection in natural conditions. Nat Rev Immunol 4(1):55–66CrossRefPubMed
52.
Quintana-Murci L, Alcais A, Abel L et al (2007) Immunology in natura: clinical, epidemiological and evolutionary genetics of infectious diseases. Nat Immunol 8(11):1165–1170CrossRefPubMed
53.
Goldstein DB, Cavalleri GL (2005) Genomics: understanding human diversity. Nature 437(7063):1241–1242CrossRefPubMed
54.
Arbour NC, Lorenz E, Schutte BC et al (2000) TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 25(2):187–191CrossRefPubMed
55.
Lorenz E, Mira JP, Frees KL et al (2002) Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch Intern Med 162(9):1028–1032CrossRefPubMed
56.
Agnese DM, Calvano JE, Hahm SJ et al (2002) Human Toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections. J Infec Dis 186(10):1522–1525CrossRef
57.
Bochud PY, Chien JW, Marr KA et al (2008) Toll-like receptor 4 polymorphisms and aspergillosis is stem cell transplantation. N Engl J Med 359(17):1766–1777CrossRefPubMed
58.
Eric G, Pamer (2008) TLR polymorphisms and the risk of invasive fungal infections. N Engl J Med 359(17):1836–1838CrossRef
59.
Tal G, Mandelberg A, Dalal I et al (2004) Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus. J Infect Dis 189(11):2057–2063CrossRefPubMed
60.
Faber J, Meyer CU, Gemmer C et al (2006) Human Toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy. Peadiart Infect Dis J 25(1):80–81CrossRef
61.
Hawn TR, Verbon A, Janer M et al (2005) Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaire’s disease. Proc Natl Acad Sci USA 102(7):2487–2489CrossRefPubMed
62.
Cooke GS, Segal S, Hill AV et al (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 347(24):1978–1980CrossRefPubMed
63.
Feterowski C, Emmanuilidis K, Miethke T et al (2003) Effects of functional Toll-like receptor 4 mutations on the immune response to human and experimental sepsis. Immunology 109(3):426–431CrossRefPubMed
64.
Ogus AC, Yoldas B, Ozdemir T et al (2004) The Arg753Gln polymorphism of the human Toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 23(2):219–223CrossRefPubMed
65.
Schroder NW, Diterich I, Zinke A et al (2005) Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia Burgdorferi and protects from late stage Lyme disease. J Immunol 175(4):2534–2540PubMed
66.
Moore CE, Segal S, Berendt AR et al (2004) Lack of association between Toll-like receptor 2 polymorphisms and susceptibility to severe disease caused by staphylococcus aureus. Clin Diagn Lab Imunol 11(6):1194–1197
67.
Yim JJ, Lee HW, Lee HS et al (2006) The association between microsatellite polymorphisms in intron II of the human Toll-like receptor 2 gene and tuberculosis among Koreans. Genes Immunol 7(2):150–155CrossRef
68.
Hawn TR, Verbon A, Lettinga KD et al (2003) A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to Legionnaire’s disease. J Exp Med 198(10):1563–1572CrossRefPubMed
69.
Dunstan SJ, Hawn TR, Hue NT et al (2005) Host susceptibility and clinical outcomes in Toll-like receptor 5 deficient patients with typhoid fever in Vietnam. J Infect Dis 191(7):1068–1071CrossRefPubMed
Metadata
Title
The Role of Toll-Like Receptor Signaling in Human Immunodeficiencies
Authors
Hanna Suhir
Amos Etzioni
Publication date
01-02-2010
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 1/2010
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-009-8135-0

Other articles of this Issue 1/2010

Clinical Reviews in Allergy & Immunology 1/2010 Go to the issue

EditorialNotes

Contemporary Challenges in Human Innate Immunodeficiency Syndromes

OriginalPaper

Hematopoetic Stem Cell Transplantation in Neutrophil Disorders: Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency and Chronic Granulomatous Disease

OriginalPaper

Chronic Granulomatous Disease

OriginalPaper

Defects in the Leukocyte Adhesion Cascade

OriginalPaper

Genetic Insights into Congenital Neutropenia

OriginalPaper

Crohn’s Disease: an Immune Deficiency State
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits